MAMAHT STUDY

PHASE II CLINICAL TRIAL OF MAMA ANTIMALARIAL HERBAL TABLETS IN ADULTS WITH UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202202608761158

Enrollment

120

Registered

2022-02-28

Start date

2022-02-14

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

ArtemeterLumefantrine group

MAMA herbal antimalarial tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. consenting patients aged 18 years and above 2. Patients with symptoms and signs of uncomplicated malaria 3. Demonstration of Plasmodium falciparum malaria in thick and thin blood film 4. Parasite density between 1,000 and 200,000 trophozoites/microlitre of blood

Exclusion criteria

Exclusion criteria: 1. Elderly patients greater than 65 years of age 2. pregnant women 3. Patients with severe malaria

Design outcomes

Primary

Measure	Time frame
Comparative reduction in parasite density with Artemether Lumefantrine	—

Secondary

Measure	Time frame
Safety profile as determined by the renal and liver function tests and hematological parameters	—

Countries

Nigeria

Contacts

Public ContactAbdulakeem Ahmed

Senior Registrar in Family Medicine

ahmediganna@gmail.com+2347039879808

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026